In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MorphoSys: Accelerating The Long Transformation

Executive Summary

Flush with funds from new partnering deals and recent capital injections, German biotech MorphoSys plans to boost its already considerable R&D spending to build value in the pipeline while holding on to promising assets longer.


Related Content

MorphoSys Hopes FDA Incentive Programs Can Boost Proprietary Plans
Evotec Drug Development Strategy Offers Little Downside, Big Upside
Deal Watch: Hep C M&A Still Thriving; Plus AstraZeneca/Synairgen, MorphoSys/Merck Serono, ViiV/J&J
Evotec Buys Bionamics For Shortcut To German Academic Gems
MorphoSys Nabs GSK As Latest Partner For RA Drug
Deals Of The Week Ponders When $2.1 Billion Is A Steal
MorphoSys Finds Right Time To Focus On Pipeline With AbD Serotec Sale To Bio-Rad Labs
MorphoSys Fills Out Pipeline With Xencor Deal
Will MorphoSys Trade Profitability for More Products, More Opportunities, and More Risk?
Amgen/Abgenix: All About a Drug


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts